Outcome prediction and reporting in nonconvulsive status epilepticus  by Leitinger, Markus et al.
Seizure 33 (2015) 99Letter to the editor
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eizOutcome prediction and reporting in noncon-
vulsive status epilepticus
Outcome prediction in status epilepticus (SE) and in particular
nonconvulsive SE (NCSE) is clinically important for patient
management as well as optimal use of resources, e.g. intensive
care beds. Whereas risk factors describe group effects, an outcome
predicting score supports clinicians in decision making concerning
individual patients. Results of studies reporting the performance of
outcome prediction scores should be appraised critically as they
may promote or misadvise the use of a score in individuals in real
life.
With great interest we read the article ‘‘Adult nonconvulsive
status epilepticus in a clinical setting: Semiology, aetiology,
treatment and outcome’’ by Power et al. [1] The clear conduct of
the study and detailed reporting add signiﬁcantly to the
understanding of NCSE, which needs more outcome data urgently.
The authors claimed to use the STESS-score (STatus Epilepticus
Severity Score) for retrospective evaluation of outcome prediction
as described in their methods section. However, they made
substantial and meaningful modiﬁcations: instead of scoring
patients older than 65 years with two points as in the original
publications [2,3], they gave one point for this age group. The
reduction of the score points in elderly patients would predispose
to reduced estimation of risk. In addition the authors deviated also
from STESS deﬁnitions in the outcome parameter of ‘‘dying or
suffering severe sequelae’’. In the original STESS score, bad
outcome was only death, but not severe sequelae [2]. We think
that both modiﬁcations may be justiﬁed, since STESS suffers from a
ceiling effect [4], but the term ‘‘STESS’’ cannot be applied to this
score. The used score may have some advantages, but needs to be
named differently and should be validated in direct comparison to
the original STESS, or to EMSE (Epidemiology based Mortality score
in SE) [5]. Finally, reporting the performance of outcome prediction
scores should include negative and positive predictive value, and
accuracy (i.e. number of true positives and true negatives, per total
population) [4]. A poor positive predictive value may outweigh the
beneﬁts as too many ‘‘false alarms’’ may impact on clinical
resources and have economical sequences.
We hope to have added information in order to better interpret
the clinically valuable data of Power et al. and to prevent some
potentially disadvantageous misinterpretations.
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